Skip to content

Study · Not a test of the peptide alone · 2025

4 results

Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes.

Kim MJ, Kim HS, Cho YK, Jung CH, Lee WJ

Diabetes research and clinical practice30 Oct 2025

PMID41175980 (opens in a new tab)DOI10.1016/j.diabres.2025.112978 (opens in a new tab)PepBankPUB-41175980
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In kidney transplant recipients with diabetes, basal insulin plus dulaglutide was linked to less HbA1c increase than multiple daily insulin injections.

    In plain wordsIn kidney transplant recipients with diabetes, basal insulin plus dulaglutide was linked to less blood sugar increase than multiple daily insulin injections.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n = 142

    Comparator
    Multiple daily insulin injections
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c change at 24 months
    0.61%
    MDI group
    HbA1c change at 24 months
    0.06%
    Basal insulin/dulaglutide group
    HbA1c change at 24 months
    6.7 mmol/mol
    MDI group
    HbA1c change at 24 months
    0.7 mmol/mol
    Basal insulin/dulaglutide group

    Source sentences

    Summary
    Glycosylated hemoglobin A1c remained stable in the basal insulin/dulaglutide group, whereas it increased at 24 months in the MDI group (+0.61 % [+6.7 mmol/mol] in the MDI group vs. +0.06 % [+0.7 mmol/mol] in the basal insulin/dulaglutide group; p = 0.02).
    2 context sentences
    Summary · context
    This study evaluated the real-world outcomes of dulaglutide in combination with basal insulin, compared to multiple daily injection (MDI) insulin regimen in kidney transplantation recipients with preexisting type 2 diabetes.
    Summary · context
    MDI users were matched with basal insulin plus dulaglutide users in a 1:1 ratio using propensity scores.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In kidney transplant recipients with diabetes, basal insulin plus dulaglutide was linked to greater weight reduction than multiple daily insulin injections.

    In plain wordsIn kidney transplant recipients with diabetes, basal insulin plus dulaglutide was linked to greater weight loss than multiple daily insulin injections.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight change
    Study

    n = 142

    Comparator
    Multiple daily insulin injections
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    1.07 kg
    MDI group (comparison group; the dulaglutide group had the greater reduction)
    Weight change
    −4.93 kg
    Basal insulin/dulaglutide group (group with greater weight reduction)

    Source sentences

    Summary
    The basal insulin/dulaglutide group achieved greater weight reduction (+1.07 kg vs. -4.93 kg; p < 0.0001).
    2 context sentences
    Summary · context
    This study evaluated the real-world outcomes of dulaglutide in combination with basal insulin, compared to multiple daily injection (MDI) insulin regimen in kidney transplantation recipients with preexisting type 2 diabetes.
    Summary · context
    MDI users were matched with basal insulin plus dulaglutide users in a 1:1 ratio using propensity scores.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In kidney transplant recipients with diabetes, eGFR did not differ significantly between basal insulin plus dulaglutide and multiple daily insulin injections after matching.

    In plain wordsIn kidney transplant recipients, kidney filtration did not differ significantly between basal insulin plus dulaglutide and multiple daily insulin injections after matching.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeeGFR
    Study

    n = 142

    Comparator
    Multiple daily insulin injections
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    The basal insulin/dulaglutide showed improvements in eGFR, although the differences were not statistically significant after matching.
    2 context sentences
    Summary · context
    This study evaluated the real-world outcomes of dulaglutide in combination with basal insulin, compared to multiple daily injection (MDI) insulin regimen in kidney transplantation recipients with preexisting type 2 diabetes.
    Summary · context
    MDI users were matched with basal insulin plus dulaglutide users in a 1:1 ratio using propensity scores.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In kidney transplant recipients with diabetes, graft outcomes did not differ significantly between basal insulin plus dulaglutide and multiple daily insulin injections.

    In plain wordsIn kidney transplant recipients, graft outcomes did not differ significantly between basal insulin plus dulaglutide and multiple daily insulin injections.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeKidney graft outcomes
    Study

    n = 142

    Comparator
    Multiple daily insulin injections
    Outcome group
    Kidney function · Kidney and urinary

    Source sentences

    Summary
    Kidney graft outcomes were not significantly different between the two groups.
    2 context sentences
    Summary · context
    This study evaluated the real-world outcomes of dulaglutide in combination with basal insulin, compared to multiple daily injection (MDI) insulin regimen in kidney transplantation recipients with preexisting type 2 diabetes.
    Summary · context
    MDI users were matched with basal insulin plus dulaglutide users in a 1:1 ratio using propensity scores.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.